Amneal revenue beats estimates as specialty portfolio gains traction
Amneal Pharmaceuticals (NASDAQ:AMRX) posted fourth-quarter net revenue of $814 million on Friday, exceeding Wall Street’s consensus estimate of $806 million.
The Bridgewater, N.J.-based company reported GAAP net income of $35 million, or $0.11 per diluted share, as it continues its strategic transition from commodity generics toward high-value complex medicines.
For the full year 2025, the company crossed the $3 billion revenue threshold, finishing at $3.02 billion with a total GAAP net profit of $72 million.
On an adjusted basis, full-year diluted earnings reached $0.83 per share.
Growth was primarily fueled by the company’s Specialty segment, including the Parkinson’s therapy CREXONT and UNITHROID, alongside strong performance from its AvKARE distribution business.
Management provided an optimistic outlook for 2026, initiating revenue guidance between $3.05 billion and $3.15 billion.
The company expects adjusted EBITDA to land between $720 million and $760 million, with adjusted diluted EPS forecasted at $0.93 to $1.03—suggesting double-digit bottom-line growth.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
